NEA Management Company, LLC - Q2 2021 holdings

$7.68 Billion is the total value of NEA Management Company, LLC's 63 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 800.0% .

 Value Shares↓ Weighting
BHG NewBRIGHT HEALTH GROUP INC$3,744,520,000218,212,128
+100.0%
48.77%
GLUE NewMONTE ROSA THERAPEUTICS INC$174,863,0007,703,205
+100.0%
2.28%
BILL NewBILL COM HLDGS INC$102,723,000560,774
+100.0%
1.34%
CVRX NewCVRX INC$66,384,0002,370,858
+100.0%
0.86%
RPHM NewRENEO PHARMACEUTICALS INC$44,662,0004,786,921
+100.0%
0.58%
STSA BuySATSUMA PHARMACEUTICALS INC$22,158,000
+25.1%
3,142,958
+4.8%
0.29%
-27.4%
ADXN NewADDEX THERAPEUTICS LTDsponsored ads$17,208,000180,000
+100.0%
0.22%
TPST NewTEMPEST THERAPEUTICS INC$1,317,000117,785
+100.0%
0.02%
VECT NewVECTIVBIO HLDG AG$782,00067,069
+100.0%
0.01%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-08-02
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
GLYCOMIMETICS INC39Q3 20237.6%
AURINIA PHARMACEUTICALS INC37Q3 20235.0%
CHAMPIONS ONCOLOGY INC33Q3 20231.2%
LEXICON PHARMACEUTICALS INC32Q3 20232.0%
ADAPTIMMUNE THERAPEUTICS PLC31Q3 20239.3%
TREVENA INC31Q3 20213.3%
AKARI THERAPEUTICS PLC31Q2 20230.3%
ARDELYX INC29Q3 202111.9%
RIGEL PHARMACEUTICALS INC29Q2 20200.6%
EPIZYME INC28Q1 20209.6%

View NEA Management Company, LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-14
13F-HR2023-11-14
13F-HR2023-08-11
13F-HR2023-05-15
13F-HR2023-02-10
13F-HR2022-11-14
13F-HR2022-08-15
13F-HR2022-05-16
13F-HR2022-02-14
13F-HR2021-11-12

View NEA Management Company, LLC's complete filings history.

Compare quarters

Export NEA Management Company, LLC's holdings